Progress Note:   Subjective: Discussed at board rounds with Dr. [**NAME**] and Dr. [**NAME**]. Ms. [**NAME**] is doing well, denies any HA or visual changes. BPs have been well controlled on Labetalol 400 TID.   Objective:  Filed Vitals:   [**DATE**] 0701 [**DATE**] 0731 [**DATE**] 0801 [**DATE**] 0837  BP: 127/64 119/67 147/84   Pulse:    100  Temp:      TempSrc:      Resp:   14   Height:      Weight:      SpO2:       FHT:130s, mod BTBV, positive accels, negative decels TOCO: none CVX: deferred  Lungs: CTAB Urine output: 100 cc/hr  R3 Ultrasound:  Singleton female fetus  Cephalic presentation  Anterior placenta, no previa  EFW = 887g (20%)  AFI = 8.43 cm  Bilateral umbilical artery dopplers with forward flow during diastole.    Data Review:   Recent Labs Lab [**DATE**] 1245 [**DATE**] 0555  WBC 8.8 15.2*  HGB 10.4* 10.6*  HCT 31.1* 32.7*  PLATCOUNT 264 271    Recent Labs Lab [**DATE**] 1245 [**DATE**] 0555 [**DATE**] 1150  BUN 7 6  --   CREATININE 0.61 0.54  --   MG 1.8 5.7* 5.6*    Recent Labs Lab [**DATE**] 1245 [**DATE**] 0555  AST 24 20  ALT 22 20   Assessment:  HD3 24 y.o. P0 @ 28w3d Transfer from [**LOCATION_INSTITUTE**] for pre-eclampsia with severe features - blood pressures requiring multiple IV treatments labetelol 10,20,40, 40; hydralazine 5, 5, 10 on HD#0.  Severe Preeclampsia - Currently normal to mild range blood pressures - Magnesium for seizure prophylaxis; UOP adequate - Labetalol 400 TID started on admission - Panel wnl, PrCr 1829; ordered daily  -Peds aware  -Consented for cesarean with possible classical uterine incision   Plan:  1. CEFM x2  2. S/p BMS [**DATE**] 1329 3. Continue Labetalol 400 mg TID. Continue to monitor BP closely  4. Will discontinue magnesium now.  5. Will continue to monitor BPs closely, possible transfer to MBU later today if stable.   [**NAME**], MD   I saw and evaluated the patient. I discussed this patient with the resident and agree with the findings and plan as documented in the resident's note 